Subtype
Hepatocellular Carcinoma
CI-CAN-00002853HCC · LIHCExplore in graph →
693 active trials13 approved drugs9 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002853HCC · LIHCExplore in graph →
Clinical trials
3,126 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (357)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04204577 | The Safety and Efficacy of Thermal Ablation Combined With Apatinib and Carilimub for Advanced Liver Cancer | unknown | Phase 2 | 90 | Chinese PLA General HospitalOTHER | 1 | Dec 19, 2019 | clinicaltrials |
| NCT04202523 | Combined Radiotherapy and Radiofrequency Ablation for Hepatocellular Carcinoma | unknown | Phase 3 | 50 | Guangxi Medical UniversityOTHER | 1 | Dec 17, 2019 | clinicaltrials |
| NCT03638206 |
| Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies |
| unknown |
| Phase 1 / Phase 2 |
| 73 |
| Shenzhen BinDeBio Ltd.INDUSTRY |
| 1 |
| Dec 11, 2019 |
| clinicaltrials |
| NCT04157140 | Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC | unknown | Phase 2 | 48 | Jinglong ChenOTHER | 1 | Dec 3, 2019 | clinicaltrials |
| NCT03851913 | The Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Beyond Milan Criteria BCLC Stage A/B Hepatocellular Carcinoma Who Underwent Hepatectomy | unknown | Phase 3 | 344 | Sun Yat-sen UniversityOTHER | 1 | Nov 29, 2019 | clinicaltrials |
| NCT04168944 | Lenvatinib Following Liver Transplantation in Patients With High-Risk Hepatocellular Carcinoma | unknown | Phase 2 / Phase 3 | 108 | RenJi HospitalOTHER | 0 | Nov 19, 2019 | clinicaltrials |
| NCT04169399 | Toripalimab Plus Stereotactic Body Radiotherapy for HCC With PVTT | unknown | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Nov 19, 2019 | clinicaltrials |
| NCT04162158 | Safety and Efficacy of Allogeneic NK Cells Therapy in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 200 | Beijing 302 HospitalOTHER | 1 | Nov 14, 2019 | clinicaltrials |
| NCT04160897 | Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated Cirrhosis | unknown | — | 4,000 | Qing XIeOTHER | 1 | Nov 13, 2019 | clinicaltrials |
| NCT04152356 | Combined Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma | unknown | — | 50 | Guangxi Medical UniversityOTHER | 1 | Nov 5, 2019 | clinicaltrials |
| NCT03825705 | A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 60 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 31, 2019 | clinicaltrials |
| NCT04069949 | Sorafenib Plus Toripalimab for Unresectable HCC With Portal Vein Tumor Thrombus(STUHCCPVTT) | unknown | Phase 1 / Phase 2 | 39 | Sichuan UniversityOTHER | 0 | Oct 25, 2019 | clinicaltrials |
| NCT03790059 | Radiofrequency Ablation Combined With Recombinant Human Adenovirus Type 5 in the Treatment of Hepatocellular Carcinoma. | unknown | N/A | 160 | Southwest Hospital, ChinaOTHER | 1 | Oct 16, 2019 | clinicaltrials |
| NCT01825824 | Stereotactic Ablative Radiotherapy for Hepatocellular Carcinoma ≤ 5 cm | unknown | Phase 2 | 54 | Korea Cancer Center HospitalOTHER | 1 | Sep 20, 2019 | clinicaltrials |
| NCT04006275 | Comparing SonoVue With Sonazoid Using CEUS-LIRADS in HCC | unknown | Phase 3 | 100 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Sep 19, 2019 | clinicaltrials |
| NCT01451658 | A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol (S-HCC) | unknown | Phase 4 | 100 | Taipei Veterans General Hospital, TaiwanOTHER_GOV | 1 | Sep 4, 2019 | clinicaltrials |
| NCT04025437 | Neoadjuvant Radiotherapy for HCC Involving Type I PVTT | unknown | Phase 2 / Phase 3 | 214 | Guangxi Medical UniversityOTHER | 1 | Sep 4, 2019 | clinicaltrials |
| NCT01970748 | Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices(P-HCC) | unknown | Phase 4 | 200 | Taipei Veterans General Hospital, TaiwanOTHER_GOV | 1 | Aug 30, 2019 | clinicaltrials |
| NCT03993743 | A Study of CD147-targeted CAR-T by Hepatic Artery Infusions for Very Advanced Hepatocellular Carcinoma | unknown | Phase 1 | 34 | Xijing HospitalOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT04066543 | TACE Combined With Anlotinib Treatment of Middle-advanced Hepatocellular Carcinoma (HCC) Patients | unknown | Phase 2 | 40 | Zhejiang Cancer HospitalOTHER | 1 | Aug 26, 2019 | clinicaltrials |
| NCT02733809 | Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 4 | 40 | King Saud UniversityOTHER | 1 | Aug 20, 2019 | clinicaltrials |
| NCT03905967 | TACE With Lenvatinib Versus Lenvatinib Alone in in First-line Treatment of Advanced HCC(TACE) | unknown | Phase 3 | 336 | Sun Yat-sen UniversityOTHER | 1 | Aug 20, 2019 | clinicaltrials |
| NCT04053972 | The Impact on Recurrence Risk of Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial. | unknown | Phase 3 | 377 | Sun Yat-sen UniversityOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT04053985 | The Efficacy of Transarterial Chemoinfusion (TAI) Combine Lenvatinib in Advanced Hepatocellular Carcinoma (HCC) | unknown | Phase 3 | 206 | Sun Yat-sen UniversityOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT04052152 | Anlotinib Hydrochloride Combined With Sintilimab Injection in the Treatment of Advanced Hepatocellular Carcinoma (HCC) | unknown | Phase 2 | 20 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 9, 2019 | clinicaltrials |
| NCT03965546 | ET 140202 -T Cell Combined With TAE or Sorafenib in the Treatment of Liver Cancer | unknown | Early Phase 1 | 27 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Aug 8, 2019 | clinicaltrials |
| NCT04048317 | Effectiveness of Drug Eluting TACE in Primary HCC | unknown | Early Phase 1 | 75 | Assiut UniversityOTHER | 0 | Aug 7, 2019 | clinicaltrials |
| NCT01936233 | Clinical Study of Antiviral and Aspirin Treatment in Liver Cancer After Radical Surgery | unknown | Phase 3 | 112 | Fudan UniversityOTHER | 1 | Aug 5, 2019 | clinicaltrials |
| NCT02529761 | TACE With or Without Sorafenib in Intermediate Stage Hepatocellular Carcinoma | unknown | N/A | 330 | Air Force Military Medical University, ChinaOTHER | 1 | Aug 1, 2019 | clinicaltrials |
| NCT04035876 | Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant | unknown | Phase 1 / Phase 2 | 120 | Zhejiang UniversityOTHER | 1 | Jul 29, 2019 | clinicaltrials |
| NCT04032392 | Immunotherapy of Advanced Hepatitis B Related Hepatocellular Carcinoma With γδT Cells | unknown | Phase 1 | 20 | Beijing 302 HospitalOTHER | 1 | Jul 25, 2019 | clinicaltrials |
| NCT04021056 | Observational Study on Patients With Hepatocellular Carcinoma (HCC) | unknown | — | 3,000 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jul 16, 2019 | clinicaltrials |
| NCT04014101 | SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular Carcinoma(SHR-1210) | unknown | Phase 2 | 40 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 11, 2019 | clinicaltrials |
| NCT04012021 | EXplanted LIver and Ex-vivo Pancreatic Specimen Evaluation by 7 TESLA MRI(EXLIPSE) | unknown | N/A | 30 | University of PisaOTHER | 1 | Jul 9, 2019 | clinicaltrials |
| NCT01570166 | Percutaneous Radiofrequency Ablation Versus Repeat Hepatectomy for Recurrent Hepatocellular Carcinoma | unknown | N/A | 210 | Sun Yat-sen UniversityOTHER | 1 | Jun 26, 2019 | clinicaltrials |
| NCT03996681 | TACE Combined With Methylcantharidimide Tablets in the Treatment of Large and Unresectable Hepatocellular Carcinoma | unknown | Phase 4 | 22 | Suzhou Municipal HospitalOTHER | 1 | Jun 25, 2019 | clinicaltrials |
| NCT03981848 | Radiomics-based Non-invasive Classifier Research for HCC-related Liver Transplantation | unknown | — | 200 | Zhejiang UniversityOTHER | 0 | Jun 11, 2019 | clinicaltrials |
| NCT03966209 | Safety and Efficacy of PD-1 Inhibitors in Patients With Liver Transplant | unknown | Phase 1 | 20 | Shanghai Zhongshan HospitalOTHER | 1 | May 31, 2019 | clinicaltrials |
| NCT03950102 | SBRT as Bridging Therapy for Hepatocellular Carcinoma Patients on Transplant Waitlist | unknown | N/A | 40 | The University of Hong KongOTHER | 1 | May 28, 2019 | clinicaltrials |
| NCT03880721 | By Developing a Radiomics Model to Predict the Prognosis of Patients With Hepatocellular Carcinoma After Microwave Ablation | unknown | — | 200 | Chinese PLA General HospitalOTHER | 1 | May 24, 2019 | clinicaltrials |
| NCT03138044 | Combined Ipsilateral Liver Lobe Devascularization and Alcohol Treatment of the Large Hepatocellular Carcinoma | unknown | N/A | 12 | The National Ribat UniversityOTHER | 1 | May 14, 2019 | clinicaltrials |
| NCT03939845 | A Prospective, Randomized, Multicenter Study of Comparison of TACE Combination With and Without EBRT for Hepatocellular Carcinoma With Portal Vein Tumor Thrombi | unknown | Phase 3 | 180 | Shanghai Zhongshan HospitalOTHER | 1 | May 7, 2019 | clinicaltrials |
| NCT03812770 | Phase 2 Study of Sorafenib Plus HAIC of FOLFOX vs. Sorafenib Plus HAIC of OXA for Advanced HCC | unknown | Phase 2 | 150 | Sun Yat-sen UniversityOTHER | 1 | Apr 17, 2019 | clinicaltrials |
| NCT03914352 | A Novel Immunotherapy PD-1 Antiboty to Suppress Recurrence of HCC Combined With PVTT After Hepatic Resection | unknown | N/A | 40 | Cancer Hospital of Guangxi Medical UniversityOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT03899415 | TCR-Redirected T Cells Therapy in Patient With HBV Related HCC | unknown | Phase 1 | 10 | Beijing 302 HospitalOTHER | 1 | Apr 10, 2019 | clinicaltrials |
| NCT03908840 | Open-label Multicenter Phase 1 Study of TBI 302 as Second-Line Therapy in Patients With Hepatocellular Carcinoma | unknown | Phase 1 | 12 | Evolve BiologicsINDUSTRY | 1 | Apr 9, 2019 | clinicaltrials |
| NCT03869151 | Pretreatment Lymphocyte Monocyte Ratio on Outcome HCC Patients | unknown | — | 1 | Amany Aboalenen AminOTHER | 0 | Apr 2, 2019 | clinicaltrials |
| NCT03857815 | Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Patients With Hepatocellular Carcinoma | unknown | Phase 2 | 30 | Shanghai Zhongshan HospitalOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT03881501 | Evaluate the Treatment With Sintilimab Injection Plus Endostar in Hepatocellular Carcinoma | unknown | — | 2 | Huazhong University of Science and TechnologyOTHER | 1 | Mar 19, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Dec 19, 2019source: clinicaltrials